Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Maze Therapeutics (MAZE) to $46 from $34 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst’s Biotechnology coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics initiated with an Overweight at Wells Fargo
- Maze Therapeutics price target raised to $60 from $50 at H.C. Wainwright
- Maze Therapeutics initiated with a Strong Buy at Raymond James
- Maze Therapeutics Reports Strong Q3 2025 Progress
- Promising Developments in Maze Therapeutics’ Pipeline: Buy Rating Reinforced by MZE829 and MZE782 Advances